COVID-19 Vaccine

Palantir, Moderna, Pfizer, Alibaba, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Netflix, TSMC, American Express, Moderna, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock
Netflix, TSMC, American Express, Moderna, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
CDC Urges Second COVID-19 Vaccine Dose For Elderly Americans Amid Rising Hospitalizations

COVID-19 Vaccine Recent News

Timing Favors Novavax's Delayed Approval, Arrival Ahead of Peak COVID Vaccine Demand
Last week, Novavax Inc (NASDAQ: NVAX) received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1.5 in 
Privatized Vaccine Distribution Sparks Confusion, Payment Challenges
As the rollout of the updated COVID-19 vaccine progresses, some individuals have been surprised by requests for upfront payments ranging from $150 to $200. 
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin
Moderna Talks Offer Hope for Enhanced COVID-19 Vaccine Availability In Europe
European countries are actively negotiating a fresh COVID-19 vaccine procurement agreement with Moderna Inc (NASDAQ: MRNA) as concerns mount within EU health authorities regarding a surge in coronavirus infections. 
Updated Covid Vaccine US Rollout Hit by Insurance Coverage Delays - What It Means?
As the U.S.
Say Goodbye to Free COVID-19 Shots: CDC Approves Priced Boosters for Omicron Subvariants
The Centers for Disease Control and Prevention (CDC) has officially endorsed COVID-19 booster shots for individuals six months and older as we approach the fall season.
Is Moderna's New Vaccine the Answer to the Highly Mutated BA.2.86 COVID-19 Variant?
Moderna Inc's (NASDAQ: MRNA) clinical trial data from its research assay confirm that its updated COVID-19 vaccine generates an 8.7-fold increase in neutralizing antibodies in humans against BA.2.86 (Pirola), 
Europe Approves Pfizer/BioNTech's Adapted COVID-19 Vaccine For Upcoming Autumn Vaccination Campaigns
The European Commission has approved Comirnaty XBB.1.5-adapted COVID-19 vaccine, developed by BioNTech SE (NASDAQ:
Money Stolen On Account COVID-19 Relief Fund Fraud is Shocking! US Justice Department Cracks Whip
The U.S.
Judge Denies Kennedy's Request To Restore His Vaccine Videos On Youtube
On Wednesday, a U.S. District Judge denied a request by Democratic presidential candidate Robert F.
Moderna, Pfizer's Updated COVID Shot Shows Effectiveness Against 'Eris' Variant In Early Human, Preclinical Studies
Moderna Inc (NASDAQ: MRNA) announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies against 
Novavax's COVID-19 Vaccine Gets Complete Approval From European Commission
The European Commission has approved Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373), following a positive opinion for a full authorization from the Committee for Medicinal Products for Human Use of the 
Moderna Seeks European Nod For Updated COVID-19 Vaccine Shot To Tackle New Dominant Strain
Moderna Inc (NASDAQ: MRNA) submitted a regulatory application to the European Medicines Agency (EMA) for its updated COVID-19 vaccine encoding the spike protein for the XBB.1.5 
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other pandemics or to support vaccine manufacturing in Africa. The initiative will conclude at the end of this year, but some of its work will continue.
Pfizer, Moderna, and Novavax Gear Up for XBB.1.5 Strain Targeted Vaccines as FDA AdCom Unanimously Support
Thursday, the FDA's Vaccines and Related Biological Products Advisory Committee all 21 members v
Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by
Novavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging Variants
Novavax Inc's (NASDAQ: NVAX) R&D chief Filip Dubovsky expressed confidence that the company's updated COVID-19 vaccine, already in production, will offer protection against the rapidly emerging coronavirus variants prevalent in the U.S.
Amended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases
BioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5 Cases
In an annual general meeting, BioNTech SE's (NASDAQ: BNTX) CEO and co-founder Ugur Sahin told shareholders the company is working on COVID-19 vaccines targeting XBB.1.5 strains in line with recommendations by the World Health Organization.
GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the
European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals
The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public pro
FDA Gives Green Signal To Second Omicron-Adapted Booster Shots For People At High Risk From Covid

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved